Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.55 |
| ▸ | LTA4H | P09960 | 9/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 5/20 | 0.48 |
| ▸ | HTR7 | P34969 | 5/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | GLS | O94925 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4145891 | 0.90 | LTA4H (0.56) | KDM1ALTA4HSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL12922895 | 0.83 | GLS (0.61) | KDM4EALDH1A1SMN1; SMN2GLS | |
| SCHEMBL13850499 | 0.83 | SMN1; SMN2 (0.52) | LTA4HSIGMAR1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4139801 | 0.83 | KDM4E (0.60) | KDM1ALTA4HSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL13850446 | 0.80 | CCR5 (0.49) | KDM1ALTA4HSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL2768717 | 0.76 | SLC7A5 (0.48) | SIGMAR1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL7399430 | 0.75 | TMEM97 (0.63) | LTA4HSIGMAR1KDM4E | |
| SCHEMBL4591522 | 0.75 | KDM4E (0.52) | LTA4HKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3334714 | 0.74 | ALDH1A1 (0.51) | KDM4EALDH1A1SMN1; SMN2GLS | |
| SCHEMBL28588436 | 0.74 | KMT2A (0.55) | KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118263-A1 | Novel Adenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118263-A1 | Novel Adenine Compound | ADORA1, ADORA2A, ADORA3 | KDM1A 841/4885LTA4H 1647/4885SIGMAR1 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.